Athersys’ (ATHX) “Buy” Rating Reaffirmed at Maxim Group
Maxim Group reissued their buy rating on shares of Athersys Inc. (NASDAQ:ATHX) in a research note released on Wednesday morning. They currently have a $10.00 price target on the biopharmaceutical company’s stock.
Other analysts also recently issued reports about the company. Zacks Investment Research upgraded Athersys from a hold rating to a buy rating and set a $2.50 target price for the company in a research note on Monday, July 11th. TheStreet upgraded Athersys from a sell rating to a hold rating in a research note on Tuesday, May 31st.
Shares of Athersys (NASDAQ:ATHX) opened at 2.06 on Wednesday. Athersys has a one year low of $0.94 and a one year high of $2.90. The stock has a 50 day moving average price of $1.97 and a 200-day moving average price of $2.19. The company’s market capitalization is $175.06 million.
Athersys (NASDAQ:ATHX) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. The company earned $0.60 million during the quarter, compared to the consensus estimate of $0.32 million. Athersys had a negative return on equity of 25.42% and a negative net margin of 18.89%. The firm’s revenue for the quarter was up 200.0% compared to the same quarter last year. During the same period last year, the business posted ($0.05) EPS. On average, equities research analysts expect that Athersys will post ($0.21) EPS for the current year.
In related news, EVP John J. Harrington sold 15,000 shares of Athersys stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $1.96, for a total value of $29,400.00. Following the sale, the executive vice president now owns 619,639 shares of the company’s stock, valued at approximately $1,214,492.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATHX. NEXT Financial Group Inc raised its position in Athersys by 1.4% in the second quarter. NEXT Financial Group Inc now owns 92,750 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 1,250 shares in the last quarter. A.R.T. Advisors LLC raised its position in Athersys by 2.5% in the second quarter. A.R.T. Advisors LLC now owns 69,953 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,715 shares in the last quarter. LPL Financial LLC raised its position in Athersys by 30.8% in the first quarter. LPL Financial LLC now owns 51,000 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 12,000 shares in the last quarter. Alambic Investment Management L.P. raised its position in Athersys by 164.3% in the second quarter. Alambic Investment Management L.P. now owns 56,300 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 35,000 shares in the last quarter. Finally, Nationwide Fund Advisors acquired a new position in Athersys during the second quarter worth $104,000. Institutional investors and hedge funds own 17.76% of the company’s stock.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Stock Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related stocks with our FREE daily email newsletter.